PODD: Partnership Opportunities in Drug Delivery Community News reposted this
Time flies. With conference season starting again, we've reflected on the autumn's innovation and announcements. Headlines below - more in the full post: ◾ Progress on High API Concentrations: a long-running theme, but important progress on both formulation (e.g. Elektrofi with new funding) and device (SMC Ltd's automated resuspension). ◾ Sustainability Remains a Topic, but Varies by Market: AstraZeneca announced a more sustainable 1ml device, but this can be a 'luxury' that lower-volume pharma assets struggle to justify early on... "we can always think about [improve] sustainability later". ◾ Growing Interest in Alternative Routes of Administration: a re-emergence of novel approaches to improve patient experience. This is especially relevant as GLP-1 reaches a broader population, with new data from Anodyne Nanotech, Inc., for example. ◾ Emerging Therapies Bring New Delivery & Supply Chain Challenges: drug stability and delivery are increasingly important for high value therapies and unstable formulations. ◾ Collaboration and Partnering Remain Critical: It's not just us saying this, promise. Many drugs don't require innovation to deliver, but more complex formulations are increasingly multidisciplinary - and often the first challenge is aligning internal stakeholders. Radical innovation is rare in a heavily regulated, high-stakes market. Progress requires the persistence, ingenuity and collaboration of teams across the industry. Keep it up, everyone.